Press release from Companies
Publicerat: 2017-12-29 08:09:05
EQL Pharma has recruited Axel Schörling as a new COO. Axel will begin his employment in mid-January 2018. Mr. Schörling will be responsible for sourcing, supply chain, pricing and working capital strategies.
He has a background as a management consultant at BearingPoint and most recently as a Director in the Business Controlling team at Perstorp. Altogether, he has an extensive experience from a number of industries and assignments with a focus on logistics and supply chain from an operational / financial perspective. Mr. Schörling will play a key role in EQL's continued development and growth. He holds a MEng in Engineering Physics from Chalmers and a MSc in Financial Economics from the Gothenburg's School of Economics.
"To take on the position as COO at EQL Pharma is as a very exciting opportunity and I think my strong background in logistics, purchasing and working capital will fit perfectly into the role. I look forward to devote my full and complete focus to support and drive EQLs growth journey" says Axel Schörling.
"EQL Pharma continues its commitment to putting new strategic niche generics on the market. In this work, Axel Schörling will play a key role, "said Christer Fåhraeus, CEO of EQL Pharma.For further information, please contact:
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 - 60 90 00
Website: www.eqlpharma.com About EQL Pharma
EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets nine (9) niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on AktieTorget. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.